Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Jan 2013
Randomized Controlled TrialPredicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score.
The aim of this study was to derive and validate a model to predict survival in candidates for HeartMate II (HMII) (Thoratec, Pleasanton, California) left ventricular assist device (LVAD) support. ⋯ The HMRS might be useful for mortality risk stratification in HMII candidates and may serve as an additional tool in the patient selection process.
-
J. Am. Coll. Cardiol. · Jan 2013
Meta AnalysisA meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
The goal of the study was to assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of cardiovascular (CV) death, myocardial infarction (MI), and stroke, and on all-cause death, new-onset heart failure (HF), and new-onset diabetes mellitus (DM) in high-risk patients without HF. ⋯ In patients at high CV risk without HF, ACE-Is and ARBs reduced the risk of the composite outcome of CV death, MI, and stroke. ACE-Is also reduced the risk of all-cause death, new-onset HF, and new-onset DM. Thus, ARBs represent a valuable option to reduce CV mortality and morbidity in patients in whom ACE-Is cannot be used.